The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma

Area of Science:

• Oncology
• Immunology
• Genetics
• Epigenetics

Background:

• Melanoma progression involves immune dysregulation and genetic/epigenetic changes leading to uncontrolled cell proliferation and metastasis.
• Advanced melanoma treatments like immunotherapy and targeted therapies face challenges due to cancer cells evading treatment.
• Persistent dormant tumor cells are a significant factor in reduced therapeutic response and treatment failure.

Purpose of the Study:

• To comprehensively review the genetic underpinnings of the dormancy and awakening phenomenon in metastatic melanoma.
• To identify potential therapeutic strategies targeting dormant melanoma cells.
• To explore methods for eliminating circulating tumor cells (CTCs) or maintaining them in a dormant state.

Main Methods:

• Comprehensive literature review focusing on genetic and epigenetic factors influencing melanoma cell dormancy.
• Analysis of mechanisms by which melanoma cells enter, maintain, and exit dormancy.
• Exploration of existing and potential therapeutic interventions targeting dormant melanoma cells and CTCs.

Main Results:

• Dormancy in melanoma is a complex state influenced by genetic and epigenetic alterations, allowing residual cells to evade current therapies.
• Understanding the molecular drivers of dormancy can reveal vulnerabilities in persistent melanoma cells.
• Circulating tumor cells (CTCs) can remain dormant, posing a risk for future relapse and metastasis.

Conclusions:

• Elucidating the genetic basis of melanoma dormancy is crucial for overcoming treatment resistance.
• Targeting dormancy mechanisms could lead to novel strategies to eliminate or control metastatic melanoma.
• Preventing melanoma relapse and spread may be achievable by managing dormant tumor cells and CTCs.